FDA
-
-
-
-
-
-
-
NRx Pharmaceuticals disputes Kadima claims amid arbitration
-
-
-
-
-
-
-
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
-
-
-
-
-
-
-
NRx Pharmaceuticals receives FDA clearance for depression trial
-
-
-
-
-
-
-
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
-
-
-
-
-
-
-
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
-
-
-
-
-
-
-
NRx Pharmaceuticals names Joshua Brown as chief medical innovation officer
-
-
-
-
-
-
-
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
-
330,512 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

